Annual Meeting

AM17 Daily News Monday

Issue link: http://read.uberflip.com/i/832905

Contents of this Issue

Navigation

Page 0 of 119

said. Research has also shown that systemic symptom moni- toring can help close this gap, and that patients are willing and able to self-report, even when they are ill or close to death. The standard model for re- porting symptoms is a reactive approach in which patients must take the initiative to re- member and report their symp- toms to health professionals, who can then take action to al- leviate the symptoms, Dr. Basch noted. In a proactive model, and closed January 2014. En- rolled patients included those with high-risk locally advanced or metastatic prostate cancer that was newly diagnosed or relapsed after radical prostatec- tion. Patients were randomly assigned 2:1 to receive olapa- rib 300 mg tablets twice daily (205 patients) or to physician's choice of chemotherapy (97 pa- tients; 91 treated). The tablet formation was developed for patient convenience, and repre- sents a slightly lower dose than the commonly available dose of 400 mg, taken in 8 capsules. Patient characteristics were well-matched between the groups, with a median age of 44 and 45, respectively; most patients were white (65%), and about half of the patients had triple-negative breast cancer (TNBC). The most commonly used chemotherapy agents in- cluded capecitabine, eribulin, and vinorelbine. The study met its primary endpoint of progression-free survival (PFS), assessed by blinded independent central re- view. The patients treated with olaparib had a median PFS of 7.0 months compared with 4.2 months with chemotherapy (hazard ratio [HR] 0.58, 95% CI MEETING COVERAGE Genomics and Bladder Cancer Treatment 8A Risk-Based Approach to Colon Cancer Chemotherapy Duration 18A Early Drug Development for Sarcoma 18A Combined Checkpoint Inhibition and CNS Therapy in Melanoma 21A In Brief 21A Post-Surgery Capecitabine New Standard of Care in Biliary Tract Cancers 22A Front-Line Bendamustine Plus Rituximab in Indolent NHL and MCL 23A Fluciclovine in Cancer Management 1B Treatment of Older Patients With Lung Cancer 1C Must-See Monday and Tuesday Sessions 1D PHYSICIAN-AUTHORED Expert Editorials ASCO and FDA's Efforts to Improve the Evidence Base for Treating Older Adults With Cancer 10A Pathways and Practice Transformation 12A Consensus Guidelines for Breast-Conserving Surgery 1B Improving International Quality Standards for Oncology Care 20B Circulating Tumor DNA as Precision Medicine Tool for Lymphoma 26B Gene Editing by CRISPR/ CAS9 in Human Cells 1C Tobacco Control 32C Clinical Corner First-Line Therapy in Advanced BRAF-Mutant Melanoma 35B Surgery After Neoadjuvant Chemotherapy in Advanced Gastric Cancer 3C ASCO NEWS CENTRA 10A 2011 Plenary Retrospective 3B 2017 GU Cancers Symposium Highlights 14B 2017 Cancer Survivorship Symposium Highlights 18C Increasing Workforce Diversity in Oncology 24C SPECIAL AWARDS Award for Excellence in Geriatric Oncology: Dr. Jean-Pierre Droz 1B Allen S. Lichter Visionary Leader Award: Dr. Patrick J. Loehrer 1C HIGHLIGHTS ASCO Daily News session coverage continues online. Visit am.asco.org/dn for exclusive coverage of Monday and Tuesday sessions. Attendee Tip of the Day See ADT Plus Abiraterone, Page 3A DAILY NEWS MONDAY ยท J U N E 5, 20 1 7 A See Olaparib, Page 3A See Reporting Symptoms Tool, Page 8A ADT Plus Abiraterone Improves Survival in Hormone-Sensitive Advanced Prostate Cancer A dding abiraterone to androgen-deprivation therapy (ADT) in- creased overall survival (OS) among men with locally advanced or hormone-sensitive metastatic prostate cancer, and the therapy was well tolerated, according to results presented from the LATITUDE (Abstract LBA3) and STAMPEDE trials (Abstract LBA5003). "Abiraterone acetate plus prednisolone should be part of the standard of care for men starting long-term ADT," Nicho- las D. James, BSc, MBBS, PhD, of Queen Elizabeth Hospital and the University of Birming- ham, in the United Kingdom, said. He presented the results of the STAMPEDE trial during the Genitourinary (Prostate) Cancer Oral Abstract Session on June 3. Approximately 3% to 5% of men diagnosed with prostate cancer have metastasis at diag- nosis in Western countries; in some large countries in Asia, however, that incidence can be as high as 60%, Karim Fizazi, MD, PhD, of the Gustave Roussy Cancer Campus and University Paris-Sud, in France, said during an ASCO Press Briefing on June 3. Dr. Fizazi presented results of the LATITUDE trial during the Plenary Session on June 4. Historically, ADT has been the standard of care for patients with hormone-sensitive, locally advanced or metastatic disease, and in the past several years docetaxel has been added to that therapy for patients with high metastatic burden. STAMPEDE Trial The STAMPEDE trial began in 2005 and is the largest random- ized clinical trial of treatments for prostate cancer. This on- going study has a multistage, multi-arm design to allow adap- tion and addition of new thera- pies. An abiraterone compari- son arm was opened in 2011 Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer Online Tool for Reporting Symptoms Extends Survival O laparib tablet mono- therapy yielded im- proved progression-free survival compared with standard-of-care chemotherapy among women with HER2- negative metastatic breast can- cer and a germline BRCA muta- tion, according to results of a phase III trial (Abstract LBA4). Mark E. Robson, MD, of Me- morial Sloan Kettering Cancer Center, presented the results of the Olympiad trial during the Plenary Session held June 4. Inhibition of poly (ADP-ri- bose) polymerase (PARP) when BRCA1/2 mutations are not present to aid in DNA damage repair can induce "synthetic lethality" in cancer cells, and some small studies suggested that PARP inhibition could be effective in patients with breast cancer when BRCA mutations are present, he said during a press briefing also held June 4. Olympiad included 302 pa- tients with HER2-negative metastatic breast cancer with a confirmed or suspected del- eterious germline BRCA muta- T he use of a web-based sys- tem that allowed patients to report symptoms to their clinicians remotely was associated with benefits in- cluding improved quality of life (QOL) and longer overall sur- vival (OS), a randomized single- center trial found. Ethan M. Basch, MD, MSc, FASCO, of The University of North Carolina at Chapel Hill, presented the findings of the study (Abstract LBA2) at the Ple- nary Session on June 4. "This approach should be considered for inclusion as a part of stan- dard symptom management," Dr. Basch said. The results of the study were published in the Jour- nal of the American Medical Asso- ciation simultaneously with the presentation. Symptoms are common in advanced cancer, and symptom management is a cornerstone of oncology practice to alleviate suffering and avoid downstream complications. However, nu- merous hurdles inhibit patient reporting of symptoms, and pre- vious research has shown that up to half of symptoms are not reported to clinicians, Dr. Basch Dr. Karim Fizazi presents LBA3.

Articles in this issue

Links on this page

view archives of Annual Meeting - AM17 Daily News Monday